Movement Alert|UiPath Falls 5.66% in Regular Trading, Q2 Flat Earnings Aftershock Persists as Most Analysts Maintain Hold Ratings

Market Focus
Sep 08

On September 8, UiPath fell 5.66% in regular trading, trading at $13.975/share, with turnover of $112 million. The stock continued to slide as the market digested the company's fiscal Q2 results and a wave of cautious analyst commentary.

UiPath reported Q2 revenue of $410.3 million, beating the FactSet consensus estimate of $397.8 million, but adjusted EPS of $0.15 was flat year-over-year, signaling stalled profit growth. Although the company raised its full-year revenue guidance to $1.789–$1.794 billion, above the prior $1.776–$1.781 billion range, Oppenheimer noted limited evidence of sustained growth re-acceleration, with the revenue beat primarily driven by professional services and licenses rather than core subscription momentum. The company also announced a CFO transition, promoting Hitesh Ramani to replace Ashim Gupta, adding to market uncertainty.

While Citigroup initiated coverage with a Buy rating and a $23 price target, the broader analyst consensus remains at Hold with a mean target of $16.96. Truist and RBC both reiterated Hold-equivalent ratings, lifting targets modestly to $17. UBS maintained Neutral at $19. The stock has declined roughly 17% since earnings were released on September 3.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10